OneSource Speciality Pharma receives SFDA approval for its generic Ozempic
The approval represents an important entry for OneSource into the Kingdom of Saudi Arabia, one of the largest markets for GLP-1 therapies, positioning the exclusive partnership to capitalise on rising demand for this product and underscoring the shared ambition of both companies to increase access to high-quality affordable generic alternatives to patients across the region.
Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state of-the-art integrated Biologics and Drug-Device Combination facility in Bengaluru and Hikma, the largest pharmaceutical company in MENA based on sales1, will use its extensive commercial reach and institutional relationships in the region to scale access across both private and institutional channels.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content